Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Coya Therapeutics Inc COYA

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:COYA)

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Business Wire 15 hours ago

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Business Wire 10 days ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Business Wire March 19, 2024

Coya Therapeutics to Participate in BTIG Fireside Discussion

Business Wire March 12, 2024

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Business Wire March 12, 2024

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Business Wire March 6, 2024

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Business Wire February 29, 2024

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

Business Wire February 22, 2024

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a "Pipeline in a Product"

Business Wire February 21, 2024

Opinion & Analysis (NDAQ:COYA)

No current opinion is available.

Bullboard Posts (NDAQ:COYA)

Huge news to start the year for COYA!

https://youtu.be/SEh4ra1xKtM?si=mMoM3EDtm0zzlUhb
BryceCanada - January 4, 2024

New video out from COYA CEO

https://youtu.be/Hg5B8IbmRxU?si=4ybR64kYvKuRUVDW
BryceCanada - October 26, 2023

Excellent YT analysis on COYA!

https://youtu.be/0AmM1T6lkN0
BryceCanada - March 6, 2023